Nonviral delivery of nCas9 for "safe harbor" integration to treat MPS IVA
Mol Ther Methods Clin Dev
.
2023 Dec 29;32(1):101178.
doi: 10.1016/j.omtm.2023.101178.
eCollection 2024 Mar 14.
Author
Li Ou
1
Affiliation
1
Avirmax Biopharma, Inc., Hayward, CA, USA.
PMID:
38178916
PMCID:
PMC10762920
DOI:
10.1016/j.omtm.2023.101178
No abstract available
Publication types
News